Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition

Matrix Biology

Volumn 32, Issue 2, 2013, Pages 95-105

  Curran, Colleen S ^a   Keely, Patricia J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Breast cancer; Fibroblast; Hypoxia; Macrophage; TGF

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RANTES; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CELL MIGRATION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HYPOXIA; MACROPHAGE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROMA CELL; TUMOR GROWTH;

ANOXIA; BREAST NEOPLASMS; CELL COMMUNICATION; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; HUMANS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84875813805     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2012.11.016     Document Type: Review

References (202)

1. Aaboe M., Offersen B.V., Christensen A., Andreasen P.A. Vitronectin in human breast carcinomas. Biochim. Biophys. Acta 2003, 1638:72-82.
2. Acosta-Iborra B., Elorza A., Olazabal I.M., Martin-Cofreces N.B., Martin-Puig S., Miro M., Calzada M.J., Aragones J., Sanchez-Madrid F., Landazuri M.O. Macrophage oxygen sensing modulates antigen presentation and phagocytic functions involving IFN-gamma production through the HIF-1 alpha transcription factor. J. Immunol. 2009, 182:3155-3164.
3. Aghaee F., Pirayesh Islamian J., Baradaran B. Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy. J. Breast Cancer 2012, 15:141-147.
4. al Adnani M.S., Taylor S., al-Bader A.A., al-Zuhair A.G., McGee J.O. Immunohistochemical localization of collagens and fibronectin in human breast neoplasms. Histol. Histopathol. 1987, 2:227-238.
5. Anand R.J., Gribar S.C., Li J., Kohler J.W., Branca M.F., Dubowski T., Sodhi C.P., Hackam D.J. Hypoxia causes an increase in phagocytosis by macrophages in a HIF-1alpha-dependent manner. J. Leukoc. Biol. 2007, 82:1257-1265.
6. Arancibia R., Oyarzun A., Silva D., Tobar N., Martinez J., Smith P.C. Tnf-alpha inhibits Tgf-beta-stimulated myofibroblastic differentiation and extracellular matrix production in human gingival fibroblasts. J. Periodontol. 2012, (Electronic publication ahead of print July 19, 2012) (PMID: 22813343).
7. Azuma Y.T., Matsuo Y., Nakajima H., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Karow M., Takeuchi T. Interleukin-19 is a negative regulator of innate immunity and critical for colonic protection. J. Pharmacol. Sci. 2011, 115:105-111.
8. Barker H.E., Cox T.R., Erler J.T. The rationale for targeting the LOX family in cancer. Nat. Rev. Cancer 2012, 12:540-552.
9. Bartram U., Speer C.P. The role of transforming growth factor beta in lung development and disease. Chest 2004, 125:754-765.
10. Bauerle T., Komljenovic D., Merz M., Berger M.R., Goodman S.L., Semmler W. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int. J. Cancer 2011, 128:2453-2462.
11. Berman A.E., Kozlova N.I., Morozevich G.E. Integrins: structure and signaling. Biochemistry (Mosc.) 2003, 68:1284-1299.
12. Bianchi-Smiraglia A., Paesante S., Bakin A.V. Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene 2012, (Electronic publication ahead of print July 23, 2012) (PMID: 22824793).
13. Braun S., Bitton-Worms K., LeRoith D. The link between the metabolic syndrome and cancer. Int. J. Biol. Sci. 2011, 7:1003-1015.
14. Brito L.G., Schiavon V.F., Andrade J.M., Tiezzi D.G., Peria F.M., Marana H.R. Expression of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor-C in locally advanced breast cancer patients. Clinics (Sao Paulo) 2011, 66:1313-1320.
15. Capparelli C., Whitaker-Menezes D., Guido C., Balliet R., Pestell T.G., Howell A., Sneddon S., Pestell R.G., Martinez-Outschoorn U., Lisanti M.P., Sotgia F. CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 2012, 11:2272-2284.
16. Cascio S., Bartella V., Auriemma A., Johannes G.J., Russo A., Giordano A., Surmacz E. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha. Oncogene 2008, 27:540-547.
17. Chakravarthy D., Green A.R., Green V.L., Kerin M.J., Speirs V. Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. Int. J. Oncol. 1999, 15:187-194.
18. Chan W.K., Yao G., Gu Y.Z., Bradfield C.A. Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways. Demonstration of competition and compensation. J. Biol. Chem. 1999, 274:12115-12123.
19. Chandramouli A., Simundza J., Pinderhughes A., Cowin P. Choreographing metastasis to the tune of LTBP. J. Mammary Gland Biol. Neoplasia 2011, 16:67-80.
20. Charpin C., Tavassoli F., Secq V., Giusiano S., Villeret J., Garcia S., Birnbaum D., Bonnier P., Lavaut M.N., Boubli L., Carcopino X., Iovanna J. Validation of an immunohistochemical signature predictive of 8-year outcome for patients with breast carcinoma. Int. J. Cancer 2012, 131:E236-E243.
21. Chen W., Gueron M. The inhibition of bovine heart hexokinase by 2-deoxy-d-glucose-6-phosphate: characterization by 31P NMR and metabolic implications. Biochimie 1992, 74:867-873.
22. Cheng G., Zielonka J., Dranka B.P., McAllister D., Mackinnon A.C., Joseph J., Kalyanaraman B. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 2012, 72:2634-2644.
23. Chiavarina B., Whitaker-Menezes D., Migneco G., Martinez-Outschoorn U.E., Pavlides S., Howell A., Tanowitz H.B., Casimiro M.C., Wang C., Pestell R.G., Grieshaber P., Caro J., Sotgia F., Lisanti M.P. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. Cell Cycle 2010, 9:3534-3551.
24. Chiavarina B., Martinez-Outschoorn U.E., Whitaker-Menezes D., Howell A., Tanowitz H.B., Pestell R.G., Sotgia F., Lisanti M.P. Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1alpha and HIF2alpha in tumor-associated fibroblasts and human breast cancer cells. Cell Cycle 2012, 11.
25. Chien W., O'Kelly J., Lu D., Leiter A., Sohn J., Yin D., Karlan B., Vadgama J., Lyons K.M., Koeffler H.P. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int. J. Oncol. 2011, 38:1741-1747.
26. Choi J.Y., Jang Y.S., Min S.Y., Song J.Y. Overexpression of MMP-9 and HIF-1alpha in breast cancer cells under hypoxic conditions. J. Breast Cancer 2011, 14:88-95.
27. Chouaib S., Messai Y., Couve S., Escudier B., Hasmim M., Noman M.Z. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front. Immunol. 2012, 3:21.
28. Conklin M.W., Eickhoff J.C., Riching K.M., Pehlke C.A., Eliceiri K.W., Provenzano P.P., Friedl A., Keely P.J. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am. J. Pathol. 2011, 178:1221-1232.
29. Connolly E.C., Freimuth J., Akhurst R.J. Complexities of TGF-beta targeted cancer therapy. Int. J. Biol. Sci. 2012, 8:964-978.
30. Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.I., Cheng P., Cho H.I., Celis E., Quiceno D.G., Padhya T., McCaffrey T.V., McCaffrey J.C., Gabrilovich D.I. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207:2439-2453.
31. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
32. Curran C.S., Bertics P.J. Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1alpha and MCP-1 in GM-CSF-treated human primary eosinophils. J. Interferon Cytokine Res. 2012, 32:450-461.
33. Denison M.S., Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 2003, 43:309-334.
34. Dobolyi A., Vincze C., Pal G., Lovas G. The neuroprotective functions of transforming growth factor beta proteins. Int. J. Mol. Sci. 2012, 13:8219-8258.
35. Doedens A.L., Stockmann C., Rubinstein M.P., Liao D., Zhang N., DeNardo D.G., Coussens L.M., Karin M., Goldrath A.W., Johnson R.S. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010, 70:7465-7475.
36. Donovan J., Slingerland J. Transforming growth factor-beta and breast cancer: cell cycle arrest by transforming growth factor-beta and its disruption in cancer. Breast Cancer Res. 2000, 2:116-124.
37. Drabsch Y., ten Dijke P. TGF-beta signaling in breast cancer cell invasion and bone metastasis. J. Mammary Gland Biol. Neoplasia 2011, 16:97-108.
38. Droppelmann C.A., Gutierrez J., Vial C., Brandan E. Matrix metalloproteinase-2-deficient fibroblasts exhibit an alteration in the fibrotic response to connective tissue growth factor/CCN2 because of an increase in the levels of endogenous fibronectin. J. Biol. Chem. 2009, 284:13551-13561.
39. Dubrovska A., Hartung A., Bouchez L.C., Walker J.R., Reddy V.A., Cho C.Y., Schultz P.G. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br. J. Cancer 2012, 107:43-52.
40. Dunn L.K., Mohammad K.S., Fournier P.G., McKenna C.R., Davis H.W., Niewolna M., Peng X.H., Chirgwin J.M., Guise T.A. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009, 4:e6896.
41. Dwarakanath B., Jain V. Targeting glucose metabolism with 2-deoxy-d-glucose for improving cancer therapy. Future Oncol. 2009, 5:581-585.
42. Eckhardt B.L., Francis P.A., Parker B.S., Anderson R.L. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat. Rev. Drug Discov. 2012, 11:479-497.
43. Egeblad M., Rasch M.G., Weaver V.M. Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 2010, 22:697-706.
44. Fadok V.A., Bratton D.L., Konowal A., Freed P.W., Westcott J.Y., Henson P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 1998, 101:890-898.
45. Fokas E., McKenna W.G., Muschel R.J. The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. Cancer Metastasis Rev. 2012, 31:823-842.
46. Friggeri A., Yang Y., Banerjee S., Park Y.J., Liu G., Abraham E. HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin. Am. J. Physiol. Cell Physiol. 2010, 299:C1267-C1276.
47. Ganapathy V., Banach-Petrosky W., Xie W., Kareddula A., Nienhuis H., Miles G., Reiss M. Luminal breast cancer metastasis is dependent on estrogen signaling. Clin. Exp. Metastasis 2012, 29:493-509.
48. Gao P., Zhang H., Dinavahi R., Li F., Xiang Y., Raman V., Bhujwalla Z.M., Felsher D.W., Cheng L., Pevsner J., Lee L.A., Semenza G.L., Dang C.V. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007, 12:230-238.
49. Garamszegi N., Garamszegi S.P., Shehadeh L.A., Scully S.P. Extracellular matrix-induced gene expression in human breast cancer cells. Mol. Cancer Res. 2009, 7:319-329.
50. Gelse K., Poschl E., Aigner T. Collagens-structure, function, and biosynthesis. Adv. Drug Deliv. Rev. 2003, 55:1531-1546.
51. Generali D., Berruti A., Brizzi M.P., Campo L., Bonardi S., Wigfield S., Bersiga A., Allevi G., Milani M., Aguggini S., Gandolfi V., Dogliotti L., Bottini A., Harris A.L., Fox S.B. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin. Cancer Res. 2006, 12:4562-4568.
52. Ghanta K.S., Pakala S.B., Reddy S.D., Li D.Q., Nair S.S., Kumar R. MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response. J. Biol. Chem. 2011, 286:7132-7138.
53. Goh F.G., Piccinini A.M., Krausgruber T., Udalova I.A., Midwood K.S. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J. Immunol. 2010, 184:2655-2662.
54. Gould V.E., Koukoulis G.K., Virtanen I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differ. Dev. 1990, 32:409-416.
55. Grande J.P., Melder D.C., Zinsmeister A.R. Modulation of collagen gene expression by cytokines: stimulatory effect of transforming growth factor-beta1, with divergent effects of epidermal growth factor and tumor necrosis factor-alpha on collagen type I and collagen type IV. J. Lab. Clin. Med. 1997, 130:476-486.
56. Green C.E., Liu T., Montel V., Hsiao G., Lester R.D., Subramaniam S., Gonias S.L., Klemke R.L. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One 2009, 4:e6713.
57. Grimshaw M.J., Naylor S., Balkwill F.R. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol. Cancer Ther. 2002, 1:1273-1281.
58. Grimshaw M.J., Wilson J.L., Balkwill F.R. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur. J. Immunol. 2002, 32:2393-2400.
59. Grotendorst G.R., Rahmanie H., Duncan M.R. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J. 2004, 18:469-479.
60. Guo Y.P., Martin L.J., Hanna W., Banerjee D., Miller N., Fishell E., Khokha R., Boyd N.F. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol. Biomarkers Prev. 2001, 10:243-248.
61. Guttery D.S., Shaw J.A., Lloyd K., Pringle J.H., Walker R.A. Expression of tenascin-C and its isoforms in the breast. Cancer Metastasis Rev. 2010, 29:595-606.
62. Hao N.B., Lu M.H., Fan Y.H., Cao Y.L., Zhang Z.R., Yang S.M. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 2012:948098.
63. Harmey J.H., Dimitriadis E., Kay E., Redmond H.P., Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann. Surg. Oncol. 1998, 5:271-278.
64. Heck J.N., Ponik S.M., Garcia-Mendoza M.G., Pehlke C.A., Inman D.R., Eliceiri K.W., Keely P.J. Microtubules regulate GEF-H1 in response to extracellular matrix stiffness. Mol. Biol. Cell 2012, 23:2583-2592.
65. Hehlgans S., Haase M., Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 2007, 1775:163-180.
66. Hielscher A.C., Qiu C., Gerecht S. Breast cancer cell-derived matrix supports vascular morphogenesis. Am. J. Physiol. Cell Physiol. 2012, 302:C1243-C1256.
67. Hitchon C., Wong K., Ma G., Reed J., Lyttle D., El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 2002, 46:2587-2597.
68. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93:266-276.
69. Hoffman C., Park S.H., Daley E., Emson C., Louten J., Sisco M., de Waal Malefyt R., Grunig G. Interleukin-19: a constituent of the regulome that controls antigen presenting cells in the lungs and airway responses to microbial products. PLoS One 2011, 6:e27629.
70. Hong H.H., Uzel M.I., Duan C., Sheff M.C., Trackman P.C. Regulation of lysyl oxidase, collagen, and connective tissue growth factor by TGF-beta1 and detection in human gingiva. Lab. Invest. 1999, 79:1655-1667.
71. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2002, 2:91-100.
72. Horiguchi M., Ota M., Rifkin D.B. Matrix control of transforming growth factor-beta function. J. Biochem. 2012, 152:321-329.
73. Hsing C.H., Cheng H.C., Hsu Y.H., Chan C.H., Yeh C.H., Li C.F., Chang M.S. Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome. Clin. Cancer Res. 2012, 18:713-725.
74. Hynes R.O., Naba A. Overview of the matrisome-an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 2012, 4:a004903.
75. Iacobuzio-Donahue C.A., Argani P., Hempen P.M., Jones J., Kern S.E. The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res. 2002, 62:5351-5357.
76. Ito A., Nakajima S., Sasaguri Y., Nagase H., Mori Y. Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br. J. Cancer 1995, 71:1039-1045.
77. Janik M.E., Litynska A., Vereecken P. Cell migration-the role of integrin glycosylation. Biochim. Biophys. Acta 2010, 1800:545-555.
78. Janssens K., ten Dijke P., Janssens S., Van Hul W. Transforming growth factor-beta1 to the bone. Endocr. Rev. 2005, 26:743-774.
79. Jian J., Yang Q., Dai J., Eckard J., Axelrod D., Smith J., Huang X. Effects of iron deficiency and iron overload on angiogenesis and oxidative stress-a potential dual role for iron in breast cancer. Free Radic. Biol. Med. 2011, 50:841-847.
80. Jiang W.G., Ablin R., Douglas-Jones A., Mansel R.E. Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol. Rep. 2003, 10:2039-2044.
81. Jin L., Yuan R.Q., Fuchs A., Yao Y., Joseph A., Schwall R., Schnitt S.J., Guida A., Hastings H.M., Andres J., Turkel G., Polverini P.J., Goldberg I.D., Rosen E.M. Expression of interleukin-1beta in human breast carcinoma. Cancer 1997, 80:421-434.
82. Jin H., Su J., Garmy-Susini B., Kleeman J., Varner J. Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res. 2006, 66:2146-2152.
83. Jin F., Brockmeier U., Otterbach F., Metzen E. New insight into the SDF-1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell CXCR4 are required for tumor cell intravasation. Mol. Cancer Res. 2012, 10:1021-1031.
84. Kadowaki M., Sangai T., Nagashima T., Sakakibara M., Yoshitomi H., Takano S., Sogawa K., Umemura H., Fushimi K., Nakatani Y., Nomura F., Miyazaki M. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. J. Cancer Res. Clin. Oncol. 2011, 137:1105-1115.
85. Kakkad S.M., Solaiyappan M., O'Rourke B., Stasinopoulos I., Ackerstaff E., Raman V., Bhujwalla Z.M., Glunde K. Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia 2010, 12:608-617.
86. Kallergi G., Markomanolaki H., Giannoukaraki V., Papadaki M.A., Strati A., Lianidou E.S., Georgoulias V., Mavroudis D., Agelaki S. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res. 2009, 11:R84.
87. Karkampouna S., Ten Dijke P., Dooley S., Kruithof-de Julio M. TGFbeta signaling in liver regeneration. Curr. Pharm. Des. 2012, 18:4103-4113.
88. Keely P.J. Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. J. Mammary Gland Biol. Neoplasia 2011, 16:205-219.
89. Khalili P., Arakelian A., Chen G., Plunkett M.L., Beck I., Parry G.C., Donate F., Shaw D.E., Mazar A.P., Rabbani S.A. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 2006, 5:2271-2280.
90. Kharaishvili G., Cizkova M., Bouchalova K., Mgebrishvili G., Kolar Z., Bouchal J. Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study. J. Clin. Pathol. 2011, 64:977-982.
91. Khasraw M., Bell R. Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Rev. Anticancer Ther. 2012, 12:1005-1013.
92. Kim J.W., Evans C., Weidemann A., Takeda N., Lee Y.S., Stockmann C., Branco-Price C., Brandberg F., Leone G., Ostrowski M.C., Johnson R.S. Loss of fibroblast HIF-1alpha accelerates tumorigenesis. Cancer Res. 2012, 72:3187-3195.
93. Kingsley D.M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 1994, 8:133-146.
94. Kleinman H.K., Klebe R.J., Martin G.R. Role of collagenous matrices in the adhesion and growth of cells. J. Cell Biol. 1981, 88:473-485.
95. Knowles H.J., Harris A.L. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res. 2001, 3:318-322.
96. Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., Onder T.T., Wang Z.C., Richardson A.L., Weinberg R.A., Orimo A. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20009-20014.
97. Koli K., Lohi J., Hautanen A., Keski-Oja J. Enhancement of vitronectin expression in human HepG2 hepatoma cells by transforming growth factor-beta 1. Eur. J. Biochem. 1991, 199:337-345.
98. Kondo S., Kubota S., Shimo T., Nishida T., Yosimichi G., Eguchi T., Sugahara T., Takigawa M. Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases. Carcinogenesis 2002, 23:769-776.
99. Korns D., Frasch S.C., Fernandez-Boyanapalli R., Henson P.M., Bratton D.L. Modulation of macrophage efferocytosis in inflammation. Front. Immunol. 2011, 2:57.
100. Krock B.L., Skuli N., Simon M.C. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2011, 2:1117-1133.
101. Kudo A. Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. Cell. Mol. Life Sci. 2011, 68:3201-3207.
102. Kurtoglu M., Gao N., Shang J., Maher J.C., Lehrman M.A., Wangpaichitr M., Savaraj N., Lane A.N., Lampidis T.J. Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther. 2007, 6:3049-3058.
103. Kurtzman S.H., Anderson K.H., Wang Y., Miller L.J., Renna M., Stankus M., Lindquist R.R., Barrows G., Kreutzer D.L. Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. Oncol. Rep. 1999, 6:65-70.
104. Kuwabara K., Ogawa S., Matsumoto M., Koga S., Clauss M., Pinsky D.J., Lyn P., Leavy J., Witte L., Joseph-Silverstein J., et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:4606-4610.
105. Lanigan F., O'Connor D., Martin F., Gallagher W.M. Molecular links between mammary gland development and breast cancer. Cell. Mol. Life Sci. 2007, 64:3159-3184.
106. Lanzafame S., Emmanuele C., Torrisi A. Correlation of alpha 2 beta 1 integrin expression with histological type and hormonal receptor status in breast carcinomas. Pathol. Res. Pract. 1996, 192:1031-1038.
107. Laoui D., Movahedi K., Van Overmeire E., Van den Bossche J., Schouppe E., Mommer C., Nikolaou A., Morias Y., De Baetselier P., Van Ginderachter J.A. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int. J. Dev. Biol. 2011, 55:861-867.
108. Laragione T., Bonetto V., Casoni F., Massignan T., Bianchi G., Gianazza E., Ghezzi P. Redox regulation of surface protein thiols: identification of integrin alpha-4 as a molecular target by using redox proteomics. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14737-14741.
109. Laskin D.L. Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem. Res. Toxicol. 2009, 22:1376-1385.
110. Le Y.J., Corry P.M. Hypoxia-induced bFGF gene expression is mediated through the JNK signal transduction pathway. Mol. Cell. Biochem. 1999, 202:1-8.
111. Lehmann G.M., Xi X., Kulkarni A.A., Olsen K.C., Pollock S.J., Baglole C.J., Gupta S., Casey A.E., Huxlin K.R., Sime P.J., Feldon S.E., Phipps R.P. The aryl hydrocarbon receptor ligand ITE inhibits TGFbeta1-induced human myofibroblast differentiation. Am. J. Pathol. 2011, 178:1556-1567.
112. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
113. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 2006, 24:99-146.
114. Li Z., Pang Y., Gara S.K., Achyut B.R., Heger C., Goldsmith P.K., Lonning S., Yang L. Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-beta in breast cancer progression. Int. J. Cancer 2012, 131:2584-2595.
115. Lin S., Wan S., Sun L., Hu J., Fang D., Zhao R., Yuan S., Zhang L. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci. 2012, 103:904-912.
116. Lopez-Lazaro M. Role of oxygen in cancer: looking beyond hypoxia. Anticancer Agents Med Chem. 2009, 9:517-525.
117. Lu X., Kang Y. Organotropism of breast cancer metastasis. J. Mammary Gland Biol. Neoplasia 2007, 12:153-162.
118. Luo B.H., Carman C.V., Springer T.A. Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 2007, 25:619-647.
119. Ma J., Xue Y., Cui W., Li Y., Zhao Q., Ye W., Zheng J., Cheng Y., Ma Y., Li S., Han T., Miao L., Yao L., Zhang J., Liu W. Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions. Cancer 2012, 118:4105-4116.
120. Maity G., Choudhury P.R., Sen T., Ganguly K.K., Sil H., Chatterjee A. Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity. Tumour Biol. 2011, 32:129-138.
121. Mansfield C.M. A review of the etiology of breast cancer. J. Natl. Med. Assoc. 1993, 85:217-221.
122. Margadant C., Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010, 11:97-105.
123. Medrek C., Ponten F., Jirstrom K., Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012, 12:306.
124. Migneco G., Whitaker-Menezes D., Chiavarina B., Castello-Cros R., Pavlides S., Pestell R.G., Fatatis A., Flomenberg N., Tsirigos A., Howell A., Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010, 9:2412-2422.
125. Moses H., Barcellos-Hoff M.H. TGF-beta biology in mammary development and breast cancer. Cold Spring Harb. Perspect. Biol. 2011, 3:a003277.
126. Mulgrew K., Kinneer K., Yao X.T., Ward B.K., Damschroder M.M., Walsh B., Mao S.Y., Gao C., Kiener P.A., Coats S., Kinch M.S., Tice D.A. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol. Cancer Ther. 2006, 5:3122-3129.
127. Munoz-Najar U.M., Neurath K.M., Vumbaca F., Claffey K.P. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 2006, 25:2379-2392.
128. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
129. Nemeth J.A., Nakada M.T., Trikha M., Lang Z., Gordon M.S., Jayson G.C., Corringham R., Prabhakar U., Davis H.M., Beckman R.A. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest. 2007, 25:632-646.
130. Nishizuka I., Ishikawa T., Hamaguchi Y., Kamiyama M., Ichikawa Y., Kadota K., Miki R., Tomaru Y., Mizuno Y., Tominaga N., Yano R., Goto H., Nitanda H., Togo S., Okazaki Y., Hayashizaki Y., Shimada H. Analysis of gene expression involved in brain metastasis from breast cancer using cDNA microarray. Breast Cancer 2002, 9:26-32.
131. Noel A., Munaut C., Boulvain A., Calberg-Bacq C.M., Lambert C.A., Nusgens B., Lapiere C.M., Foidart J.M. Modulation of collagen and fibronectin synthesis in fibroblasts by normal and malignant cells. J. Cell. Biochem. 1992, 48:150-161.
132. Noel A., Munaut C., Nusgens B., Foidart J.M., Lapiere C.M. The stimulation of fibroblasts' collagen synthesis by neoplastic cells is modulated by the extracellular matrix. Matrix 1992, 12:213-220.
133. Noel A., Hajitou A., L'Hoir C., Maquoi E., Baramova E., Lewalle J.M., Remacle A., Kebers F., Brown P., Calberg-Bacq C.M., Foidart J.M. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int. J. Cancer 1998, 76:267-273.
134. Nurminskaya M.V., Belkin A.M. Cellular functions of tissue transglutaminase. Int. Rev. Cell Mol. Biol. 2012, 294:1-97.
135. Oh K., Ko E., Kim H.S., Park A.K., Moon H.G., Noh D.Y., Lee D.S. Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res. 2011, 13:R96.
136. Ohtake F., Fujii-Kuriyama Y., Kawajiri K., Kato S. Cross-talk of dioxin and estrogen receptor signals through the ubiquitin system. J. Steroid Biochem. Mol. Biol. 2011, 127:102-107.
137. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
138. Paszek M.J., Weaver V.M. The tension mounts: mechanics meets morphogenesis and malignancy. J. Mammary Gland Biol. Neoplasia 2004, 9:325-342.
139. Patsialou A., Wyckoff J., Wang Y., Goswami S., Stanley E.R., Condeelis J.S. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res. 2009, 69:9498-9506.
140. Pearson O.H., Manni A., Arafah B.M. Antiestrogen treatment of breast cancer: an overview. Cancer Res. 1982, 42:3424s-3429s.
141. Philippeaux M.M., Bargetzi J.P., Pache J.C., Robert J., Spiliopoulos A., Mauel J. Culture and functional studies of mouse macrophages on native-like fibrillar type I collagen. Eur. J. Cell Biol. 2009, 88:243-256.
142. Porporato P.E., Dhup S., Dadhich R.K., Copetti T., Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol. 2011, 2:49.
143. Preissner K.T. Structure and biological role of vitronectin. Annu. Rev. Cell Biol. 1991, 7:275-310.
144. Provenzano P.P., Eliceiri K.W., Campbell J.M., Inman D.R., White J.G., Keely P.J. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006, 4:38.
145. Provenzano P.P., Inman D.R., Eliceiri K.W., Beggs H.E., Keely P.J. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am. J. Pathol. 2008, 173:1551-1565.
146. Provenzano P.P., Inman D.R., Eliceiri K.W., Keely P.J. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009, 28:4326-4343.
147. Prud'homme G.J., Glinka Y., Toulina A., Ace O., Subramaniam V., Jothy S. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 2010, 5:e13831.
148. Puig-Kroger A., Sanz-Rodriguez F., Longo N., Sanchez-Mateos P., Botella L., Teixido J., Bernabeu C., Corbi A.L. Maturation-dependent expression and function of the CD49d integrin on monocyte-derived human dendritic cells. J. Immunol. 2000, 165:4338-4345.
149. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003, 33:49-54.
150. Ramirez N.E., Zhang Z., Madamanchi A., Boyd K.L., O'Rear L.D., Nashabi A., Li Z., Dupont W.D., Zijlstra A., Zutter M.M. The alpha(2)beta(1) integrin is a metastasis suppressor in mouse models and human cancer. J. Clin. Invest. 2011, 121:226-237.
151. Ridley A.J. Rho proteins and cancer. Breast Cancer Res. Treat. 2004, 84:13-19.
152. Rose D.P., Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr. Relat. Cancer 2012, 19:R225-R241.
153. Rykala J., Przybylowska K., Majsterek I., Pasz-Walczak G., Sygut A., Dziki A., Kruk-Jeromin J. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol. Oncol. Res. 2011, 17:809-817.
154. Saad S., Gottlieb D.J., Bradstock K.F., Overall C.M., Bendall L.J. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res. 2002, 62:283-289.
155. Sakamoto T., Seiki M. A membrane protease regulates energy production in macrophages by activating hypoxia-inducible factor-1 via a non-proteolytic mechanism. J. Biol. Chem. 2010, 285:29951-29964.
156. Sakamoto T., Niiya D., Seiki M. Targeting the Warburg effect that arises in tumor cells expressing membrane type-1 matrix metalloproteinase. J. Biol. Chem. 2011, 286:14691-14704.
157. Saller M.M., Prall W.C., Docheva D., Schonitzer V., Popov T., Anz D., Clausen-Schaumann H., Mutschler W., Volkmer E., Schieker M., Polzer H. Increased stemness and migration of human mesenchymal stem cells in hypoxia is associated with altered integrin expression. Biochem. Biophys. Res. Commun. 2012, 423:379-385.
158. Sawada Y., Tamada M., Dubin-Thaler B.J., Cherniavskaya O., Sakai R., Tanaka S., Sheetz M.P. Force sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell 2006, 127:1015-1026.
159. Schiemann W.P. Targeted TGF-beta chemotherapies: friend or foe in treating human malignancies?. Expert Rev. Anticancer Ther. 2007, 7:609-611.
160. Schmid M.C., Avraamides C.J., Foubert P., Shaked Y., Kang S.W., Kerbel R.S., Varner J.A. Combined blockade of integrin-alpha4beta1 plus cytokines SDF-1alpha or IL-1beta potently inhibits tumor inflammation and growth. Cancer Res. 2011, 71:6965-6975.
161. Schultze A., Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs 2010, 19:777-788.
162. Schulz V.J., Smit J.J., Bol-Schoenmakers M., Duursen M.B., van den Berg M., Pieters R.H. Activation of the aryl hydrocarbon receptor reduces the number of precursor and effector T cells, but preserves thymic CD4(+)CD25(+)Foxp3(+) regulatory T cells. Toxicol. Lett. 2012, 215:100-109.
163. Schulze A., Downward J. Flicking the Warburg switch-tyrosine phosphorylation of pyruvate dehydrogenase kinase regulates mitochondrial activity in cancer cells. Mol. Cell 2011, 44:846-848.
164. Schwertfeger K.L., Rosen J.M., Cohen D.A. Mammary gland macrophages: pleiotropic functions in mammary development. J. Mammary Gland Biol. Neoplasia 2006, 11:229-238.
165. Seifeddine R., Dreiem A., Tomkiewicz C., Fulchignoni-Lataud M.C., Brito I., Danan J.L., Favaudon V., Barouki R., Massaad-Massade L. Hypoxia and estrogen co-operate to regulate gene expression in T-47D human breast cancer cells. J. Steroid Biochem. Mol. Biol. 2007, 104:169-179.
166. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
167. Shao R., Bao S., Bai X., Blanchette C., Anderson R.M., Dang T., Gishizky M.L., Marks J.R., Wang X.F. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol. Cell. Biol. 2004, 24:3992-4003.
168. Shimoda M., Mellody K.T., Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin. Cell Dev. Biol. 2010, 21:19-25.
169. Shi-Wen X., Leask A., Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 2008, 19:133-144.
170. Silberstein G.B., Flanders K.C., Roberts A.B., Daniel C.W. Regulation of mammary morphogenesis: evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-beta 1. Dev. Biol. 1992, 152:354-362.
171. Soikkeli J., Podlasz P., Yin M., Nummela P., Jahkola T., Virolainen S., Krogerus L., Heikkila P., von Smitten K., Saksela O., Holtta E. Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am. J. Pathol. 2010, 177:387-403.
172. Sols A., Crane R.K. Substrate specificity of brain hexokinase. J. Biol. Chem. 1954, 210:581-595.
173. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008, 267:271-285.
174. Sorrell J.M., Caplan A.I. Fibroblasts-a diverse population at the center of it all. Int. Rev. Cell Mol. Biol. 2009, 276:161-214.
175. Spangenberg C., Lausch E.U., Trost T.M., Prawitt D., May A., Keppler R., Fees S.A., Reutzel D., Bell C., Schmitt S., Schiffer I.B., Weber A., Brenner W., Hermes M., Sahin U., Tureci O., Koelbl H., Hengstler J.G., Zabel B.U. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res. 2006, 66:3715-3725.
176. Stern M., Savill J., Haslett C. Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Mediation by alpha v beta 3/CD36/thrombospondin recognition mechanism and lack of phlogistic response. Am. J. Pathol. 1996, 149:911-921.
177. Stewart D.A., Yang Y., Makowski L., Troester M.A. Basal-like breast cancer cells induce phenotypic and genomic changes in macrophages. Mol. Cancer Res. 2012, 10:727-738.
178. Sugiyama Y., Kakoi K., Kimura A., Takada I., Kashiwagi I., Wakabayashi Y., Morita R., Nomura M., Yoshimura A. Smad2 and Smad3 are redundantly essential for the suppression of iNOS synthesis in macrophages by regulating IRF3 and STAT1 pathways. Int. Immunol. 2012, 24:253-265.
179. Tall E.G., Bernstein A.M., Oliver N., Gray J.L., Masur S.K. TGF-beta-stimulated CTGF production enhanced by collagen and associated with biogenesis of a novel 31-kDa CTGF form in human corneal fibroblasts. Invest. Ophthalmol. Vis. Sci. 2010, 51:5002-5011.
180. Taylor M.A., Amin J.D., Kirschmann D.A., Schiemann W.P. Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-beta signaling in breast cancer cells. Neoplasia 2011, 13:406-418.
181. Taylor-Papadimitriou J., Burchell J., Hurst J. Production of fibronectin by normal and malignant human mammary epithelial cells. Cancer Res. 1981, 41:2491-2500.
182. Thornton R.D., Lane P., Borghaei R.C., Pease E.A., Caro J., Mochan E. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem. J. 2000, 350(Pt 1):307-312.
183. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 2006, 1:119-150.
184. Toda S., Hanayama R., Nagata S. Two-step engulfment of apoptotic cells. Mol. Cell. Biol. 2012, 32:118-125.
185. Toth B., Garabuczi E., Sarang Z., Vereb G., Vamosi G., Aeschlimann D., Blasko B., Becsi B., Erdodi F., Lacy-Hulbert A., Zhang A., Falasca L., Birge R.B., Balajthy Z., Melino G., Fesus L., Szondy Z. Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells. J. Immunol. 2009, 182:2084-2092.
186. Turner L., Scotton C., Negus R., Balkwill F. Hypoxia inhibits macrophage migration. Eur. J. Immunol. 1999, 29:2280-2287.
187. van Grevenynghe J., Rion S., Le Ferrec E., Le Vee M., Amiot L., Fauchet R., Fardel O. Polycyclic aromatic hydrocarbons inhibit differentiation of human monocytes into macrophages. J. Immunol. 2003, 170:2374-2381.
188. Vasaturo F., Sallusti E., Gradilone A., Malacrino C., Nardo T., Avagnano G., Agliano A.M., Granato T., De Vincenzi B., Coppotelli G., Marzullo A., Soda G., Simonelli L., Modesti M., Scarpa S. Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast. Int. J. Oncol. 2005, 27:1005-1011.
189. Vinothini G., Aravindraja C., Chitrathara K., Nagini S. Correlation of matrix metalloproteinases and their inhibitors with hypoxia and angiogenesis in premenopausal patients with adenocarcinoma of the breast. Clin. Biochem. 2011, 44:969-974.
190. von Drygalski A., Tran T.B., Messer K., Pu M., Corringham S., Nelson C., Ball E.D. Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support. Int. J. Breast Cancer 2011, 2011:523276.
191. Wang M.Y., Chen P.S., Prakash E., Hsu H.C., Huang H.Y., Lin M.T., Chang K.J., Kuo M.L. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 2009, 69:3482-3491.
192. Wick A.N., Drury D.R., Nakada H.I., Wolfe J.B. Localization of the primary metabolic block produced by 2-deoxyglucose. J. Biol. Chem. 1957, 224:963-969.
193. Wozniak M.A., Desai R., Solski P.A., Der C.J., Keely P.J. ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J. Cell Biol. 2003, 163:583-595.
194. Xie B., Laouar A., Huberman E. Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/gelatinase (MMP-9) gene expression during macrophage differentiation. The signaling role of protein kinase C-beta. J. Biol. Chem. 1998, 273:11576-11582.
195. Ye J., Xu R.H., Taylor-Papadimitriou J., Pitha P.M. Sp1 binding plays a critical role in Erb-B2- and v-ras-mediated downregulation of alpha2-integrin expression in human mammary epithelial cells. Mol. Cell. Biol. 1996, 16:6178-6189.
196. Yi J.M., Kwon H.Y., Cho J.Y., Lee Y.J. Estrogen and hypoxia regulate estrogen receptor alpha in a synergistic manner. Biochem. Biophys. Res. Commun. 2009, 378:842-846.
197. Ying H., Biroc S.L., Li W.W., Alicke B., Xuan J.A., Pagila R., Ohashi Y., Okada T., Kamata Y., Dinter H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol. Cancer Ther. 2006, 5:2158-2164.
198. Zhang N., Walker M.K. Crosstalk between the aryl hydrocarbon receptor and hypoxia on the constitutive expression of cytochrome P4501A1 mRNA. Cardiovasc. Toxicol. 2007, 7:282-290.
199. Zhang Y., Zhang G., Li J., Tao Q., Tang W. The expression analysis of periostin in human breast cancer. J. Surg. Res. 2010, 160:102-106.
200. Zhao Y., Min C., Vora S.R., Trackman P.C., Sonenshein G.E., Kirsch K.H. The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J. Biol. Chem. 2009, 284:1385-1393.
201. Zilberberg L., Todorovic V., Dabovic B., Horiguchi M., Courousse T., Sakai L.Y., Rifkin D.B. Specificity of latent TGF-beta binding protein (LTBP) incorporation into matrix: role of fibrillins and fibronectin. J. Cell. Physiol. 2012, 227:3828-3836.
202. Zucker S., Cao J. Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?. Cancer Biol. Ther. 2009, 8:2371-2373.